[HTML][HTML] Remdesivir for the treatment of COVID‐19
F Grundeis, K Ansems, K Dahms… - … of systematic reviews, 2023 - ncbi.nlm.nih.gov
Background Remdesivir is an antiviral medicine approved for the treatment of mild‐to‐
moderate coronavirus disease 2019 (COVID‐19). This led to widespread implementation …
moderate coronavirus disease 2019 (COVID‐19). This led to widespread implementation …
[HTML][HTML] Pharmacological treatment of COVID-19: an opinion paper
A García-Lledó, J Gómez-Pavón… - Revista Española de …, 2022 - ncbi.nlm.nih.gov
The precocity and efficacy of the vaccines developed so far against COVID-19 has been the
most significant and saving advance against the pandemic. The development of vaccines …
most significant and saving advance against the pandemic. The development of vaccines …
[HTML][HTML] Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis
Background The benefits of remdesivir in the treatment of hospitalized patients with COVID-
19 remain debated with the National Institutes of Health and the World Health Organization …
19 remain debated with the National Institutes of Health and the World Health Organization …
The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: A systematic review and meta-analysis
C Chen, J Fang, S Chen, MJN Rajaofera, X Li… - BMC Infectious …, 2023 - Springer
Background Remdesivir is considered to be a specific drug for treating coronavirus disease
2019. This systematic review aims to evaluate the clinical efficacy and risk of remdesivir …
2019. This systematic review aims to evaluate the clinical efficacy and risk of remdesivir …
Major update 2: remdesivir for adults with COVID-19: a living systematic review and meta-analysis for the American College of Physicians practice points
AS Kaka, R MacDonald, EJ Linskens… - Annals of internal …, 2022 - acpjournals.org
Background: Remdesivir is approved for the treatment of adults hospitalized with COVID-19.
Purpose: To update a living review of remdesivir for adults with COVID-19. Data Sources …
Purpose: To update a living review of remdesivir for adults with COVID-19. Data Sources …
Post-COVID-19 syndrome clinical manifestations: A systematic review
M Abdel-Gawad, MS Zaghloul… - Anti-Inflammatory & …, 2022 - ingentaconnect.com
Background: Coronavirus disease-2019 (COVID-19) is a global pandemic health problem
that causes a wide spectrum of clinical manifestations and considerable mortality rates …
that causes a wide spectrum of clinical manifestations and considerable mortality rates …
Remdesivir for the treatment of COVID‐19
Cochrane Haematology Group… - Cochrane Database …, 1996 - cochranelibrary.com
Background Remdesivir is an antiviral medicine approved for the treatment of mild‐to‐
moderate coronavirus disease 2019 (COVID‐19). This led to widespread implementation …
moderate coronavirus disease 2019 (COVID‐19). This led to widespread implementation …
Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies
ES Vaz, SV Vassiliades, J Giarolla, MC Polli… - European Journal of …, 2023 - Springer
Introduction Drug repositioning is a strategy to identify a new therapeutic indication for
molecules that have been approved for other conditions, aiming to speed up the traditional …
molecules that have been approved for other conditions, aiming to speed up the traditional …
A comprehensive review on the efficacy of several pharmacologic agents for the treatment of COVID-19
Simple Summary Treatments for coronavirus disease-2019 (COVID-19) have utilized a
variety of medications, including antivirals, immunomodulators, and other therapeutics such …
variety of medications, including antivirals, immunomodulators, and other therapeutics such …
Clinical antiviral efficacy of remdesivir in coronavirus disease 2019: an open-label, randomized controlled adaptive platform trial (PLATCOV)
P Jittamala, WHK Schilling, JA Watson… - The Journal of …, 2023 - academic.oup.com
Background Uncertainty over the therapeutic benefit of parenteral remdesivir in coronavirus
disease 2019 (COVID-19) has resulted in varying treatment guidelines. Methods In a …
disease 2019 (COVID-19) has resulted in varying treatment guidelines. Methods In a …